Company

Bristol Myers Squibb

Official Name: Bristol-Myers Squibb Company

Headquarters: New York, NY, United States

Founded: 1887

Employees: 32,200

CEO: Dr. Giovanni Caforio M.D.

show_chart NYSE: BMY +0.31%

Market Cap

$170.56 Billion

USD as of April 1, 2022

history Market Cap History

Company Description

Bristol Myers Squibb Company, also known as BMS, is a multinational pharmaceutical company. Tracing its origins to1858, it develops and manufactures prescription pharmaceuticals and biologics for a diverse range of diseases including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.

Bristol Myers Squibb market capitalization evolution

Evolution of Bristol-Myers Squibb Company market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Bristol-Myers Squibb Company

Detailed Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Wikipedia Introduction

Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. BMS is one of the world's largest pharmaceutical companies, and is consistently ranked on the Fortune 500 list of the largest U.S. corporations. As of September 2020, it had total revenue of $39.3 billion. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders. BMS's primary R&D sites are located in Lawrence, New Jersey (formerly Squibb, near Princeton), Summit, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey, Redwood City, California, and Boudry in Switzerland, with other sites in Devens and Cambridge, Massachusetts, East Syracuse, New York, Braine-l'Alleud, Belgium, Tokyo, Japan, Bangalore, India, and Wirral, United Kingdom. BMS previously had an R&D site in Wallingford, Connecticut (formerly Bristol-Myers).

Source: Wikipedia, retrieved on March 31, 2022, 8:43 p.m.

Stocks & Indices

Bristol-Myers Squibb Company has the following listings and related stock indices.


Stock: NYSE: BMY

Stock: FSX: BRM

Stock: XETR: BRM

Key People

Founder(s): William Mc Laren Bristol John Ripley Myers E. R. Squibb

Giovanni Caforio, M. D. (Chairman & CEO) David Elkins (CFO)

Financials

Revenue: US$42.518 billion (2020)

Operating income: US$30.745 billion (2020)

Net income: US$8.995 billion (2020)


Total assets: US$129.44 billion (2019)

Total equity: US$59.70 billion (2019)

Details

Headquarters:

430 East 29th Street

14th Floor

New York, NY 10016

United States

Phone: 212 546 4000